ConductScience.org, home

Paper42434745

Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis.

Yang Y and 4 others. Front Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis. Papers, record 42434745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42434745

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis.
PubMed
Journal
Front Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Systematic Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang YYang
2Sun JJinhan
3Luo TTing
4Liu XXinfu
5Wang YYanyang

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138909011
Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a Nationwide Inpatient Database.
Clin Lung Cancer2024https://conductscience.org/library/papers/38909011PubMed
234699691The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Cancer Commun (Lond)2021https://conductscience.org/library/papers/34699691PubMed
341697515Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.Adv Ther2026https://conductscience.org/library/papers/41697515PubMed
441512290Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors.J Natl Cancer Inst2026https://conductscience.org/library/papers/41512290PubMed
533538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
639958229Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon EGFR mutations: a retrospective multi-center Chinese study.Transl Lung Cancer Res2025https://conductscience.org/library/papers/39958229PubMed
740086102The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows".Cancer Treat Rev2025https://conductscience.org/library/papers/40086102PubMed
830152040Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.Thorac Cancer2018https://conductscience.org/library/papers/30152040PubMed
941820542Assessment of pneumonitis in patients with lung cancer undergoing radioimmunotherapy and immune checkpoint inhibitor rechallenge.Commun Med (Lond)2026https://conductscience.org/library/papers/41820542PubMed
1033569332Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival.Transl Lung Cancer Res2021https://conductscience.org/library/papers/33569332PubMed
1141419100Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.Cancer Lett2026https://conductscience.org/library/papers/41419100PubMed
1233588109Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.J Thorac Oncol2021https://conductscience.org/library/papers/33588109PubMed
1340136350Lung Cancer: Targeted Therapy in 2025.Curr Oncol2025https://conductscience.org/library/papers/40136350PubMed
1433220395
Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial.
Int J Radiat Oncol Biol Phys2021https://conductscience.org/library/papers/33220395PubMed
1536841540Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.J Thorac Oncol2023https://conductscience.org/library/papers/36841540PubMed
1638828946Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.N Engl J Med2024https://conductscience.org/library/papers/38828946PubMed
1740480013Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.Lung Cancer2025https://conductscience.org/library/papers/40480013PubMed
1834799993Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.Thorac Cancer2022https://conductscience.org/library/papers/34799993PubMed
1938278303Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.J Thorac Oncol2024https://conductscience.org/library/papers/38278303PubMed
2040313586
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).
Lung Cancer (Auckl)2025https://conductscience.org/library/papers/40313586PubMed

See all 27 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42434745

GET https://conductscience.org/api/papers/v1/42434745/references?page=2